Routine Early 68Ga-DOTATATE Positron Emission Tomography Has Low Yield After Resection of Appendiceal Neuroendocrine Neoplasms

被引:4
作者
Chan, David L. [1 ,2 ,3 ]
Hoang, Jeremy [1 ]
Roach, Paul J. [1 ,4 ]
Arena, Jennifer [5 ]
Bailey, Dale L. [1 ]
Nevell, David [6 ]
Pavlakis, Nick [2 ,3 ]
Engel, Alexander [7 ]
Bernard, Elizabeth J. [1 ,7 ]
机构
[1] Royal North Shore Hosp, Dept Nucl Med, Sydney, NSW, Australia
[2] Royal North Shore Hosp, Dept Med Oncol, Sydney, NSW, Australia
[3] Kolling Inst, Bill Walsh Translat Canc Res Lab, Sydney, NSW, Australia
[4] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[5] Royal North Shore Hosp, Dept Surg, New South Wales Hlth Pathol, Sydney, NSW, Australia
[6] Royal North Shore Hosp, Dept Anat Pathol, New South Wales Hlth Pathol, Sydney, NSW, Australia
[7] Royal North Shore Hosp, Dept Colorectal Surg, Sydney, NSW, Australia
基金
英国医学研究理事会;
关键词
neuroendocrine tumor; follow-up; DOTATATE PET; TUMORS; DIAGNOSIS; PET/CT;
D O I
10.1097/MPA.0000000000001589
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives Appendiceal neuroendocrine neoplasms (appNEN) generally carry a low recurrence risk.Ga-68-DOTATATE positron emission tomography (DOTA PET) is increasingly used as it is more sensitive than cross-sectional imaging. We hypothesize that early DOTA PET is unlikely to detect recurrent disease in patients with low-risk resected appNEN because of the delayed pattern of recurrence. Methods Retrospective study (dual review) of patients undergoing DOTA PET 0 to 18 months after resected appNEN. The primary outcome was the proportion of scans demonstrating residual disease. Results Forty-one patients were included (median age, 29 years; 63% female), most with small, low-grade appNEN. No scans (0%) showed residual/distant disease. Eight (20%) of 41 scans showed indeterminate findings requiring follow-up. Five (12%) scans were recommended for follow-up with modalities other than DOTA PET (vertebra, 3; thyroid; bone, 1 each). Three (7%) were recommended for follow-up with DOTA PET (all with indeterminate abdominal uptake). These 3 patients had no recurrent disease on follow-up. Conclusions The(68)Ga-DOTATATE PET is of no value when performed in the first 18 months after resected appNEN. Although 20% of scans showed indeterminate findings, more than half did not require repeat DOTA PET. Despite advantages over cross-sectional imaging, DOTA PET is not recommended in staging after completely resected appNEN.
引用
收藏
页码:891 / 896
页数:6
相关论文
共 14 条
  • [1] Appendiceal neuroendocrine neoplasms: diagnosis and management
    Alexandraki, Krystallenia I.
    Kaltsas, Gregory A.
    Grozinsky-Glasberg, Simona
    Chatzellis, Eleftherios
    Grossman, Ashley B.
    [J]. ENDOCRINE-RELATED CANCER, 2016, 23 (01) : R27 - R41
  • [2] ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Follow-Up and Documentation
    Arnold, Rudolf
    Chen, Yuan-Jia
    Costa, Frederico
    Falconi, Massimo
    Gross, David
    Grossman, Ashley B.
    Hyrdel, Rudolf
    Kos-Kudla, Beata
    Salazar, Ramon
    Ploeckinger, Ursula
    [J]. NEUROENDOCRINOLOGY, 2009, 90 (02) : 227 - 233
  • [3] Aslani Alireza, 2014, Asia Ocean J Nucl Med Biol, V2, P75
  • [4] Bosman FT., 2010, WHO CLASSIFICATION T
  • [5] Standardized Uptake Values of 68Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine Tumors
    Campana, Davide
    Ambrosini, Valentina
    Pezzilli, Raffaele
    Fanti, Stefano
    Labate, Antonio Maria Morselli
    Santini, Donatella
    Ceccarelli, Claudio
    Nori, Francesca
    Franchi, Roberto
    Corinaldesi, Roberto
    Tomassetti, Paola
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (03) : 353 - 359
  • [6] Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance
    Chan, David L. H.
    Pavlakis, Nick
    Schembri, Geoffrey P.
    Bernard, Elizabeth J.
    Hsiao, Edward
    Hayes, Aimee
    Barnes, Tristan
    Diakos, Connie
    Khasraw, Mustafa
    Samra, Jaswinder
    Eslick, Enid
    Roach, Paul J.
    Engel, Alexander
    Clarke, Stephen J.
    Bailey, Dale L.
    [J]. THERANOSTICS, 2017, 7 (05): : 1149 - 1158
  • [7] Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
    Dasari, Arvind
    Shen, Chan
    Halperin, Daniel
    Zhao, Bo
    Zhou, Shouhao
    Xu, Ying
    Shih, Tina
    Yao, James C.
    [J]. JAMA ONCOLOGY, 2017, 3 (10) : 1335 - 1342
  • [8] 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
    Deppen, Stephen A.
    Blume, Jeffrey
    Bobbey, Adam J.
    Shah, Chirayu
    Graham, Michael M.
    Lee, Patricia
    Delbeke, Dominique
    Walker, Ronald C.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (06) : 872 - 878
  • [9] Neuroendocrine Tumor Recurrence: Diagnosis with 68Ga-DOTATATE PET/CT
    Haug, Alexander R.
    Cindea-Drimus, Ramona
    Auernhammer, Christoph J.
    Reincke, Martin
    Beuschlein, Felix
    Waengler, Bjoern
    Uebleis, Christopher
    Schmidt, Gerwin P.
    Spitzweg, Christine
    Bartenstein, Peter
    Hacker, Marcus
    [J]. RADIOLOGY, 2014, 270 (02) : 517 - 525
  • [10] Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
    Hope, Thomas A.
    Bergsland, Emily K.
    Bozkurt, Murat Fani
    Graham, Michael
    Heaney, Anthony P.
    Herrmann, Ken
    Howe, James R.
    Kulke, Matthew H.
    Kunz, Pamela L.
    Mailman, Josh
    May, Lawrence
    Metz, David C.
    Millo, Corina
    O'Dorisio, Sue
    Reidy-Lagunes, Diane L.
    Soulen, Michael C.
    Strosberg, Jonathan R.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (01) : 66 - 74